Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(23):1675-1677; doi:10.1093/jnci/djj500
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Offit, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Offit, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

EDITORIAL

BRCA Mutation Frequency and Penetrance: New Data, Old Debate

Kenneth Offit

Correspondence to: Kenneth Offit, MD, MPH, Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021 (e-mail: offitk@mskcc.org).

The first 10% of the full text of this article appears below.

More than a decade after the discovery of the BRCA1 and BRCA2 genes, a consensus has yet to emerge regarding the frequency and precise magnitude and spectrum of cancer risks for individuals carrying mutations of these genes. Although these questions constitute a topic of heated debate among cancer epidemiologists (1–9), they are also of clinical concern to women and men considering BRCA testing and the various options, including preventive surgeries, if such testing produces a positive finding (10,11). The study by Risch et al. (12) not only helps to settle some of these issues but also adds interesting new data to an . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Raskin, F. Lejbkowicz, O. Barnett-Griness, S. Dishon, R. Almog, and G. Rennert
BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews
Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1617 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. R. Ferrone, D. A. Levine, L. H. Tang, P. J. Allen, W. Jarnagin, M. F. Brennan, K. Offit, and M. E. Robson
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
J. Clin. Oncol., January 20, 2009; 27(3): 433 - 438.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Offit and J. E. Garber
Time to Check CHEK2 in Families With Breast Cancer?
J. Clin. Oncol., February 1, 2008; 26(4): 519 - 520.
[Full Text] [PDF]

Home page
 NEJMHome page
M. Robson and K. Offit
Management of an Inherited Predisposition to Breast Cancer
N. Engl. J. Med., July 12, 2007; 357(2): 154 - 162.
[Full Text] [PDF]